secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0001213900-24-008015
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix receives CMS reimbursement determination for DefenCath; sets WAC price at $249.99 per vial
--------------------------------------------------------------------------------

- CMS determined DefenCath eligible for ESRD PPS reimbursement; CorMedix submitted TDAPA application for 5-year add-on payment.
- List price (WAC) set at $249.99 per 3mL vial; company committed to reduce price if Part B reimbursement is granted.
- Reiterates inpatient launch target of April 15, 2024; outpatient launch target of July 1, 2024, contingent on CMS TDAPA approval.
- Company will notify CMS to adjust inpatient NTAP reimbursement now that a WAC price is established.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024008015/0001213900-24-008015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024008015/ea192430-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-008015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer